We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

260 hedge funds and large institutions have $3.09B invested in Axsome Therapeutics in 2024 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 96 increasing their positions, 75 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 26

28% more repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 75

7% more funds holding

Funds holding: 244 → 260 (+16)

1% less capital invested

Capital invested by funds: $3.12B → $3.09B (-$30.4M)

1.03% less ownership

Funds ownership: 82.88% → 81.84% (-1%)

25% less call options, than puts

Call options by funds: $49.5M | Put options by funds: $66.4M

31% less funds holding in top 10

Funds holding in top 10: 13 → 9 (-4)

Holders
260
Holders Change
+16
Holders Change %
+6.56%
% of All Funds
3.75%
Holding in Top 10
9
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-30.77%
% of All Funds
0.13%
New
45
Increased
96
Reduced
75
Closed
26
Calls
$49.5M
Puts
$66.4M
Net Calls
-$16.9M
Net Calls Change
-$54.8M

Top Buyers

1
Macquarie Group
Macquarie Group
Australia
+$56.5M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$36.7M
3
DTC
Deep Track Capital
Connecticut
+$25.6M
4
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$23.5M
5
EAM
Eagle Asset Management
Florida
+$19M

Top Sellers

1
BI
BVF Inc
California
-$158M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$38.5M
3
Pictet Asset Management
Pictet Asset Management
Switzerland
-$29.1M
4
TCM
Tang Capital Management
California
-$25.5M
5
Morgan Stanley
Morgan Stanley
New York
-$24.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$359M +$259K +3,083 +0.1%
Vanguard Group
2
Vanguard Group
Pennsylvania
$298M +$3.65M +43,512 +1%
BlackRock
3
BlackRock
New York
$255M -$3.71M -44,256 -1%
FFM
4
Fairmount Funds Management
Pennsylvania
$188M – – –
DTC
5
Deep Track Capital
Connecticut
$104M +$25.6M +304,721 +30%
Citadel Advisors
6
Citadel Advisors
Florida
$91.3M +$4.58M +54,559 +5%
PA
7
Perceptive Advisors
New York
$88.2M +$5.65M +67,322 +6%
RCM
8
RA Capital Management
Massachusetts
$79.8M – – –
Morgan Stanley
9
Morgan Stanley
New York
$75.3M -$24.8M -294,875 -24%
State Street
10
State Street
Massachusetts
$74.9M +$1.22M +14,526 +2%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$67.5M +$1.94M +23,103 +3%
Fidelity Investments
12
Fidelity Investments
Massachusetts
$66.1M -$4.49M -53,477 -6%
Millennium Management
13
Millennium Management
New York
$59.2M -$14.1M -168,447 -19%
ACM
14
Alethea Capital Management
Washington
$59.1M -$945K -11,253 -1%
Macquarie Group
15
Macquarie Group
Australia
$55.9M +$56.5M +672,886 +2,445%
BG
16
Bellevue Group
Switzerland
$54.7M +$4.21M +50,104 +8%
Wellington Management Group
17
Wellington Management Group
Massachusetts
$54M +$36.7M +436,827 +182%
HRCM
18
Hood River Capital Management
Florida
$41.6M +$10.7M +127,997 +33%
Adage Capital Partners
19
Adage Capital Partners
Massachusetts
$41.1M +$12.6M +150,000 +41%
PHS
20
PFM Health Sciences
California
$37.3M – – –
APM
21
Avidity Partners Management
Texas
$34.4M -$2.38M -28,400 -6%
BC
22
Boxer Capital
California
$31.9M – – –
Norges Bank
23
Norges Bank
Norway
$30.8M +$16M +190,428 +98%
Point72 Asset Management
24
Point72 Asset Management
Connecticut
$30.2M -$38.5M -458,337 -55%
WP
25
Woodline Partners
California
$28.7M -$17M -202,035 -36%
1
2 3 4 5

AXSM Hedge Fund Activity: Q1 2024 in Review

260 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2024, worth a combined $3.09B — down 0.98% from $3.12B a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new AXSM positions and 26 closed out — a net gain of 19 holders — while 96 added to existing stakes and 75 trimmed.

The largest buyer was Macquarie Group, adding an estimated $56.5M. The largest seller was BVF Inc, exiting entirely with an estimated $158M sold.

  • 260 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2024, up from 244 in Q4 2023.
  • Funds reported $3.09B of Axsome Therapeutics stock for Q1 2024, down 0.98% quarter-over-quarter.
  • 45 funds opened new Axsome Therapeutics positions in Q1 2024 and 26 closed out, a net change of +19 holders.
  • The largest Axsome Therapeutics buyer in Q1 2024 was Macquarie Group, an estimated $56.5M added.
  • The largest Axsome Therapeutics seller in Q1 2024 was BVF Inc, an estimated $158M sold.

Based on aggregated 13F filings for Q1 2024.